Unity Biotechnology, Inc.
LSE: 0YC0.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Anirvan Ghosh
- Employees
- 16
- Headquarters
- South San Francisco, United States
- IPO year
- 2018
- Market cap
- $1.0M
- Website
- https://unitybiotechnology.com
Loading 0YC0…
Loading profile data…Frequently asked questions about 0YC0
What does Unity Biotechnology, Inc. (0YC0.L) do?
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...
Where does 0YC0.L trade?
Unity Biotechnology, Inc. (0YC0.L) trades on the London Stock Exchange.
What sector is 0YC0.L in?
Unity Biotechnology, Inc. (0YC0.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Unity Biotechnology, Inc.?
Anirvan Ghosh is the chief executive officer of Unity Biotechnology, Inc. (0YC0.L).
Where is Unity Biotechnology, Inc. headquartered?
Unity Biotechnology, Inc. is headquartered in United States.
Does 0YC0.L pay a dividend?
Unity Biotechnology, Inc. (0YC0.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0YC0.L go public?
Unity Biotechnology, Inc. (0YC0.L) completed its initial public offering in 2018.